Evidence map›Paper›PMID 37719963›Full record

ArticleJournal of clinical and translational hepatology2023

Clinical Significance of Apurinic/Apyrimidinic Endodeoxyribonuclease 1 and MicroRNA Axis in Hepatocellular Carcinoma.

Giovanna Mangiapane, Devis Pascut, Emiliano Dalla, Giulia Antoniali, Monica Degrassi, Lory Saveria Crocè, Veronica De Sanctis, Silvano Piazza, Giulia Canarutto, Claudio Tiribelli and 1 more

Abstract read
In one paragraph

Article in Journal of clinical and translational hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. [Analysis ofZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giovanna MangiapaneLaboratory of Molecular Biology and DNA Repair, Department of Medicine, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0001-6633-0481
Devis PascutFondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy.ORCID https://orcid.org/0000-0003-0583-1973
Emiliano DallaLaboratory of Molecular Biology and DNA Repair, Department of Medicine, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0002-4687-6011
Giulia AntonialiLaboratory of Molecular Biology and DNA Repair, Department of Medicine, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0002-2639-1893
Monica DegrassiLaboratory of Molecular Biology and DNA Repair, Department of Medicine, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0002-2816-4803
Lory Saveria CrocèFondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy.ORCID https://orcid.org/0000-0001-9890-7011
Veronica De SanctisNGS Core Facility, Department CIBIO, University of Trento, Trento, Italy.ORCID https://orcid.org/0000-0002-9791-5316
Silvano PiazzaComputational Biology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy.
Giulia CanaruttoComputational Biology, International Centre for Genetic Engineering and Biotechnology, ICGEB, Trieste, Italy.ORCID https://orcid.org/0000-0001-5010-7269
Claudio TiribelliFondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy.ORCID https://orcid.org/0000-0001-6596-7595
Gianluca TellLaboratory of Molecular Biology and DNA Repair, Department of Medicine, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0001-8845-6448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Identification of prognostic factors for hepatocellular carcinoma (HCC) opens new perspectives for therapy. Circulating and cellular onco-miRNAs are noncoding RNAs which can control the expression of genes involved in oncogenesis through post-transcriptional mechanisms. These microRNAs (miRNAs) are considered novel prognostic and predictive factors in HCC. The apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) contributes to the quality control and processing of specific onco-miRNAs and is a negative prognostic factor in several tumors. The present work aims to: a) define APE1 prognostic value in HCC; b) identify miRNAs regulated by APE1 and their relative target genes and c) study their prognostic value. Methods: We used The Cancer Genome Atlas (commonly known as TCGA) data analysis to evaluate the expression of APE1 in HCC. To identify differentially-expressed miRNAs (DEmiRNAs) upon APE1 depletion through specific small interfering RNA, we used NGS and nanostring approaches in the JHH-6 HCC tumor cell line. Bioinformatics analyses were performed to identify signaling pathways involving APE1-regulated miRNAs. Microarray analysis was performed to identify miRNAs correlating with serum APE1 expression. Results: APE1 is considerably overexpressed in HCC tissues compared to normal liver, according to the TCGA-liver HCC (known as LIHC) dataset. Enrichment analyses showed that APE1-regulated miRNAs are implicated in signaling and metabolic pathways linked to cell proliferation, transformation, and angiogenesis, identifying Cyclin Dependent Kinase 6 and Lysosomal Associated Membrane Protein 2 as targets. miR-33a-5p, miR-769, and miR-877 are related to lower overall survival in HCC patients. Through array profiling, we identified eight circulating DE-miRNAs associated with APE1 overexpression. A training phase identified positive association between sAPE1 and miR-3180-3p and miR-769. Conclusions: APE1 regulates specific miRNAs having prognostic value in HCC.

Indexed as

APE1Hepatocellular carcinomamiRNAsPrognostic factors

Identifiers

PMID37719963
PMCPMC10500290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.